Background: Population pharmacokinetics (PK) of azithromycin (AZ) and chloroquine (CQ) following administration of fixed-dose combination tablet formulations of AZ and CQ (AZCQ) was evaluated using data from two studies: 1) in children with symptomatic uncomplicated falciparum malaria in sub-Saharan Africa; and 2) in healthy adults in the United States.

Methods: Study 1 included paediatric subjects randomized to either AZCQ or artemether-lumefantrine treatment in Cohort 1 (age 5-12 years) and Cohort 2 (age 6-59 months). Dosing of AZCQ was approximately 30 mg/kg AZ and 10 mg/kg CQ once daily for 3 days (for ≥20 kg weight: AZ/CQ 300/100 mg per tablet; 5 to <20 kg weight: AZ/CQ 150/50 mg per tablet). Study 2 included adults randomized to receive either two AZCQ tablets (AZ/CQ 250/155 mg per tablet) or individual commercial tablets of AZ 500 mg and CQ 300 mg. Serum AZ and plasma CQ concentrations from both studies were pooled. Population PK models were constructed using standard approaches to evaluate the concentration-time data for AZ and CQ and to identify any covariates predictive of PK behaviour.

Results: A three-compartment PK model with linear clearance and absorption adequately described AZ data, while a two-compartment model with linear clearance and absorption and an absorption lag adequately described CQ data. No overall bias or substantial model misspecification was evident using diagnostic plots and visual predictive checks. Body weight as an allometric function was the only covariate in the final AZ and CQ PK models. There were significantly lower AZ (0.488 vs 0.745 [mg•h/L]/[mg/kg], p < 0.00001) and CQ (0.836 vs 1.27 [mg•h/L]/[mg/kg], p < 0.00001) exposures (AUCinf) normalized by dose (mg/kg) in children compared with the adults.

Conclusions: The PK of AZ and CQ following administration of AZCQ was well described using a three- and two-compartment model, respectively. AZ and CQ exhibited linear absorption and clearance; the model for CQ included an absorption lag. Weight was predictive of exposure for both AZ and CQ. Assuming equivalent dosing (mg/kg), AZ and CQ exposure in children would be expected to be lower than that in adults, suggesting that children may require a higher dose (mg/kg) than adults to achieve the same AZ and CQ exposure.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3909452PMC
http://dx.doi.org/10.1186/1475-2875-13-36DOI Listing

Publication Analysis

Top Keywords

azithromycin chloroquine
12
population pharmacokinetics
8
pharmacokinetics azithromycin
8
healthy adults
8
administration fixed-dose
8
cohort age
8
chloroquine healthy
4
adults paediatric
4
paediatric malaria
4
malaria subjects
4

Similar Publications

Objective: Hydroxychloroquine paired with Azithromycin, Vitamin C, Vitamin D, and Zinc (HAZDPac), was used as a multidrug therapy method to treat COVID-19 illness and superimposed secondary bacterial pneumonia. Concerns have been raised though about such combinations regarding cardiac QTc interval prolongation and risks of arrhythmias, which we set out to address in this study.

Design: We evaluated cardiac safety in a Phase II Double-Blind Randomized Placebo-Controlled Trial of Combination Therapy to Treat COVID-19 Infections study, conducted by ProgenaBiome.

View Article and Find Full Text PDF

Efficacy of Ivermectin, Chloroquine/Hydroxychloroquine, and Azithromycin in Managing COVID-19: A Systematic Review of Phase III Clinical Trials.

Biomedicines

September 2024

Laboratory of Molecular Biology and Genetics, Laboratory of Clinical and Molecular Microbiology, LunGuardian Research Group-Epidemiology of Respiratory and Infectious Diseases, São Francisco University, Bragança Paulista 12916-900, SP, Brazil.

During the coronavirus disease (COVID)-19 pandemic several drugs were used to manage the patients mainly those with a severe phenotype. Potential drugs were used off-label and major concerns arose from their applicability to managing the health crisis highlighting the importance of clinical trials. In this context, we described the mechanisms of the three repurposed drugs [Ivermectin-antiparasitic drug, Chloroquine/Hydroxychloroquine-antimalarial drugs, and Azithromycin-antimicrobial drug]; and, based on this description, the study evaluated the clinical efficacy of those drugs published in clinical trials.

View Article and Find Full Text PDF
Article Synopsis
  • COVID-19, caused by the SARS-CoV-2 virus, emerged as a major global health threat after being identified in late 2019, with the World Health Organization declaring the pandemic over on May 5, 2023.
  • Current management strategies for COVID-19 include vaccination and using repurposed medications like antimalarials and antibiotics to relieve symptoms linked to severe respiratory issues.
  • Despite attempts to repurpose antiviral drugs such as chloroquine and remdesivir for COVID-19 treatment, their inefficacy and side effects have limited their use, highlighting the ongoing challenge of dealing with this virus and its variants.
View Article and Find Full Text PDF
Article Synopsis
  • - The study evaluates the effects of hydroxychloroquine (HCQ) on ECG parameters, particularly the QTc interval, in 109 COVID-19 patients alongside the coadministration of azithromycin and levofloxacin, comparing results to a control group.
  • - Results showed that HCQ alone or with levofloxacin significantly prolonged the QTc interval, while the combination with azithromycin had a less severe effect.
  • - Long-term use of HCQ in patients with Sjogren's syndrome did not affect QTc intervals, highlighting the differing safety profiles of HCQ based on treatment context and patient factors, emphasizing the need for careful monitoring during acute treatments like COVID-19.
View Article and Find Full Text PDF
Article Synopsis
  • - The COVID-19 pandemic has struggled due to a lack of effective antiviral treatments for SARS-CoV-2, highlighting the need for better therapeutic options.
  • - Previous reliance on vaccines alone hasn't been sufficient, partly because of the virus's rapid evolution, leading researchers to explore drug repurposing as a promising strategy.
  • - This study reports positive results from a multidrug therapy approach using combinations like hydroxychloroquine and azithromycin, which could help reduce drug resistance and offer new treatment avenues for COVID-19.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!